Sodium Hyaluronate Gel Versus Lidocaine Cream for Endotracheal Tube Lubrication (SHG vs LC)
Superiority of Sodium Hyaluronate Gel Over Lidocaine Cream for Endotracheal Tube Lubrication in Reducing Postoperative Throat Numbness: A Randomized Controlled Trial
This study is a prospective, randomized, single-blind, parallel-group, single-center clinical trial in adults undergoing elective laparoscopic surgery under general anesthesia with endotracheal intubation. It will compare sterile medical sodium hyaluronate gel with lidocaine cream as a lubricant applied to the distal portion and cuff surface of the endotracheal tube. The study aims to evaluate whether sodium hyaluronate gel is superior to lidocaine cream in reducing postoperative throat numbness. The primary outcome is throat numbness assessed using a visual analog scale (VAS) 30 minutes after surgery. Secondary outcomes include throat numbness at other specified time points, coughing during emergence and after the first oral water intake, postoperative sore throat, hoarseness, endotracheal tube cuff pressure, hemodynamic responses during intubation and extubation, satisfaction, and adverse events. A total of 120 participants are planned, with 60 participants in each group.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Fan Xueyan Fan
- Telefonnummer: +86 19801288101
- E-Mail: fxya05413@btch.edu.cn
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Adults aged 18 to 65 years, of either sex.
- American Society of Anesthesiologists (ASA) physical status I or II.
- Patients scheduled for elective laparoscopic surgery under general anesthesia with endotracheal intubation.
- Expected surgical duration of 1 to 4 hours.
- Able to understand the study and provide written informed consent.
Exclusion Criteria:
- Patients expected to be transferred to the intensive care unit (ICU) postoperatively.
- Known or anticipated difficult airway.
- History of severe respiratory disease, such as asthma or chronic obstructive pulmonary disease.
- High risk of gastroesophageal reflux or aspiration, including a full stomach or a history of severe gastroesophageal reflux disease.
- Known allergy to sodium hyaluronate, lidocaine, or any other study-related medication/product.
- Pre-existing sore throat or hoarseness before surgery.
- Pregnancy or breastfeeding.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Medical sodium hyaluronate lubricating gel
A volume of 2-3 mL of sterile medical sodium hyaluronate lubricating gel (manufacturer identified in the protocol as Bloomage Biotechnology) will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation. |
A volume of 2-3 mL of sterile medical sodium hyaluronate lubricating gel (manufacturer identified in the protocol as Bloomage Biotechnology) will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation. The protocol lists medical device registration certificate number |
|
Aktiver Komparator: Lidocaine cream
A volume of 2-3 mL of lidocaine cream will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation. |
A volume of 2-3 mL of lidocaine cream will be evenly applied to the distal end and cuff surface of the endotracheal tube before intubation. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Throat numbness intensity
Zeitfenster: 30 minutes after extubation
|
Throat numbness intensity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no throat numbness, whereas a score of 10 indicates the most severe imaginable throat numbness. Higher scores indicate more severe throat numbness. |
30 minutes after extubation
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Throat numbness intensity
Zeitfenster: Immediately after extubation, 1 hour, 8 hours, 16 hours, and 24 hours.
|
Throat numbness intensity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no throat numbness, whereas a score of 10 indicates the most severe imaginable throat numbness. Higher scores indicate more severe throat numbness. |
Immediately after extubation, 1 hour, 8 hours, 16 hours, and 24 hours.
|
|
Time to first oral water intake and incidence of coughing during the first water intake
Zeitfenster: From extubation to the first oral water intake, within 24 hours after extubation.
|
The time from extubation to the first oral water intake will be recorded in minutes. The occurrence of coughing during the first water intake will also be recorded. |
From extubation to the first oral water intake, within 24 hours after extubation.
|
|
Severity of coughing during emergence from general anesthesia
Zeitfenster: During emergence from general anesthesia, from the end of anesthesia to 5 minutes after extubation.
|
Coughing during emergence and extubation will be graded as follows: 0 = no cough; 1 = mild, single cough; 2 = moderate, more than one cough with a duration of less than 5 seconds; 3 = severe, cough lasting more than 5 seconds. Suctioning during emergence will be recorded. No routine suctioning will be performed at extubation or during the first 5 minutes after extubation, unless clinically required. |
During emergence from general anesthesia, from the end of anesthesia to 5 minutes after extubation.
|
|
Postoperative sore throat severity
Zeitfenster: Immediately after extubation, and at 30 minutes, 1 hour, 8 hours, 16 hours, and 24 hours after extubation.
|
Postoperative sore throat severity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no sore throat, whereas a score of 10 indicates the most severe imaginable postoperative sore throat. Higher scores indicate more severe sore throat. |
Immediately after extubation, and at 30 minutes, 1 hour, 8 hours, 16 hours, and 24 hours after extubation.
|
|
Postoperative hoarseness severity
Zeitfenster: Immediately after extubation, and at 30 minutes, 1 hour, 8 hours, 16 hours, and 24 hours after extubation.
|
Postoperative hoarseness severity will be assessed using the 11-point Visual Analogue Scale (VAS), ranging from 0 to 10. A score of 0 indicates no hoarseness , whereas a score of 10 indicates the most severe imaginable postoperative sore throat. Higher scores indicate more severe hoarseness . |
Immediately after extubation, and at 30 minutes, 1 hour, 8 hours, 16 hours, and 24 hours after extubation.
|
|
Endotracheal tube cuff pressure measured in cmH₂O
Zeitfenster: At 1, 2, and 3 hours after intubation, and immediately before extubation.
|
Endotracheal tube cuff pressure will be measured using a cuff pressure manometer. The pressure will be recorded in cmH₂O. |
At 1, 2, and 3 hours after intubation, and immediately before extubation.
|
|
Incidence of hemodynamic abnormalities assessed by heart rate and blood pressure measurements
Zeitfenster: During tracheal extubation
|
Heart rate (HR), systolic blood pressure (SBP), and diastolic blood pressure (DBP) will be monitored and recorded. Hemodynamic abnormalities are defined as HR greater than 100 beats/min or less than 60 beats/min; SBP ≥140 mmHg and/or DBP ≥90 mmHg; or a decrease in SBP of more than 20% from baseline. |
During tracheal extubation
|
|
Anesthesiologists' satisfaction with the assigned endotracheal tube lubricant
Zeitfenster: Immediately after tracheal intubation.
|
Anesthesiologists' satisfaction with the assigned lubricant will be evaluated using a 5-point Likert scale, with scores ranging from 1 (very dissatisfied) to 5 (very satisfied). Higher scores indicate greater satisfaction. |
Immediately after tracheal intubation.
|
|
Patient satisfaction with the anesthesia recovery process
Zeitfenster: Within 2 hours after completion of surgery, during the post-anesthesia care unit (PACU) stay and before PACU discharge.
|
Patient satisfaction with the anesthesia recovery process will be assessed using a 5-point Likert scale during the PACU stay. Scores range from 1 (very dissatisfied) to 5 (very satisfied), with higher scores indicating greater satisfaction. |
Within 2 hours after completion of surgery, during the post-anesthesia care unit (PACU) stay and before PACU discharge.
|
|
Incidence of adverse events associated with the study interventions
Zeitfenster: From administration of the assigned lubricant until 24 hours after extubation.
|
The occurrence of adverse events, including allergic reactions, laryngospasm, aspiration, nausea, and vomiting, will be recorded and compared between the two groups. |
From administration of the assigned lubricant until 24 hours after extubation.
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 27014-4-02
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .